These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Systemic administration of beta2-adrenoceptor agonists, formoterol and salmeterol, elicit skeletal muscle hypertrophy in rats at micromolar doses. Ryall JG; Sillence MN; Lynch GS Br J Pharmacol; 2006 Mar; 147(6):587-95. PubMed ID: 16432501 [TBL] [Abstract][Full Text] [Related]
3. Long-term clenbuterol administration alters the isometric contractile properties of skeletal muscle from normal and dystrophin-deficient mdx mice. Hayes A; Williams DA Clin Exp Pharmacol Physiol; 1994 Oct; 21(10):757-65. PubMed ID: 7867226 [TBL] [Abstract][Full Text] [Related]
4. Intramuscular beta2-agonist administration enhances early regeneration and functional repair in rat skeletal muscle after myotoxic injury. Ryall JG; Schertzer JD; Alabakis TM; Gehrig SM; Plant DR; Lynch GS J Appl Physiol (1985); 2008 Jul; 105(1):165-72. PubMed ID: 18436698 [TBL] [Abstract][Full Text] [Related]
5. Power output of fast and slow skeletal muscles of mdx (dystrophic) and control mice after clenbuterol treatment. Lynch GS; Hinkle RT; Faulkner JA Exp Physiol; 2000 May; 85(3):295-9. PubMed ID: 10825417 [TBL] [Abstract][Full Text] [Related]
6. Modulation of insulin-like growth factor (IGF)-I and IGF-binding protein interactions enhances skeletal muscle regeneration and ameliorates the dystrophic pathology in mdx mice. Schertzer JD; Gehrig SM; Ryall JG; Lynch GS Am J Pathol; 2007 Oct; 171(4):1180-8. PubMed ID: 17823291 [TBL] [Abstract][Full Text] [Related]
7. Making fast-twitch dystrophic muscles bigger protects them from contraction injury and attenuates the dystrophic pathology. Gehrig SM; Koopman R; Naim T; Tjoakarfa C; Lynch GS Am J Pathol; 2010 Jan; 176(1):29-33. PubMed ID: 19959813 [TBL] [Abstract][Full Text] [Related]
14. Contractile function and low-intensity exercise effects of old dystrophic (mdx) mice. Hayes A; Williams DA Am J Physiol; 1998 Apr; 274(4):C1138-44. PubMed ID: 9575811 [TBL] [Abstract][Full Text] [Related]
15. GLPG0492, a novel selective androgen receptor modulator, improves muscle performance in the exercised-mdx mouse model of muscular dystrophy. Cozzoli A; Capogrosso RF; Sblendorio VT; Dinardo MM; Jagerschmidt C; Namour F; Camerino GM; De Luca A Pharmacol Res; 2013 Jun; 72():9-24. PubMed ID: 23523664 [TBL] [Abstract][Full Text] [Related]
16. IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice. Lynch GS; Cuffe SA; Plant DR; Gregorevic P Neuromuscul Disord; 2001 Apr; 11(3):260-8. PubMed ID: 11297941 [TBL] [Abstract][Full Text] [Related]
17. Force and power output of diaphragm muscle strips from mdx and control mice after clenbuterol treatment. Lynch GS; Hinkle RT; Faulkner JA Neuromuscul Disord; 2001 Mar; 11(2):192-6. PubMed ID: 11257477 [TBL] [Abstract][Full Text] [Related]
18. Systemic administration of IGF-I enhances oxidative status and reduces contraction-induced injury in skeletal muscles of mdx dystrophic mice. Schertzer JD; Ryall JG; Lynch GS Am J Physiol Endocrinol Metab; 2006 Sep; 291(3):E499-505. PubMed ID: 16621899 [TBL] [Abstract][Full Text] [Related]